CrowdfundedWealth

Oaktree Specialty Lending 10-K, Fiscal 2026: NAV $15.63, Non-Accruals 4.0% of Cost, $0.32 Dividend

ResearchBy Jorge21 min read2 SEC filings cited

Some links pay us a referral fee; each one says so. Disclosure

Filing alert · free

An email when Oaktree Specialty Lending files with the SEC

An email the day Oaktree Specialty Lending files something new, with the link to the document on the SEC site.

Quick answer

Oaktree Specialty Lending Corporation (Nasdaq: OCSL, SEC CIK 1414932) filed its Form 10-K for the year ended September 30, 2026 on November 17, 2026 (accession 0001414932-26-000023), with an 8-K the same day carrying the results (accession 0001193125-26-464682). NAV per share was $15.63 at September 30, 2026, from $15.70 at June 30, 2026 and $16.64 at September 30, 2025 (down 6.1% in the year, our arithmetic). Adjusted net investment income (NII) was $0.34 a share for the quarter and $1.49 for the year, against $1.47 of distributions declared for the year (101%, our arithmetic). The board declared $0.32 a share ($0.30 plus a $0.02 supplemental) payable December 31, 2026 to holders of record on December 15, 2026. Six investments were on non-accrual, $106.1 million at cost (4.0% of debt investments) and $45.0 million at fair value (1.8%), from ten, $181.4 million and $80.7 million a year earlier. Realized losses for the year were $73.9 million. The last reported price in the 10-K, $12.16 on November 13, 2026, was a 22.2% discount to NAV. As of November 17, 2026.

Key takeaways

  • The dividend is covered by a thin margin and the supplemental keeps shrinking. Adjusted NII was $1.49 a share in fiscal 2026 against $1.47 declared (101%, our arithmetic), after $1.76 against $1.84 (96%, our arithmetic) in fiscal 2025. For the December 2026 quarter the board declared $0.32, which is $0.30 plus $0.02; the total declared for the quarter ended September 30, 2026 was $0.33 and for the quarter ended June 30, 2026 $0.34 (10-K, Item 5). Quarterly adjusted NII was $0.34, 106% of $0.32 (our arithmetic).
  • NAV fell $1.01 in the year, and realized losses did most of it. The 10-K's per-share bridge is $16.64, plus $1.51 of NII, minus $0.21 of unrealized loss, minus $0.84 of realized loss, minus $1.47 of distributions, equals $15.63. Realized net losses were $73.9 million, led by Dominion Diagnostics ($24.5 million), Mosaic Companies ($18.0 million), Astra Acquisition ($16.8 million) and BAART Programs ($11.3 million). Note 8 names five of the ten companies on the September 2025 non-accrual list as realized losses and a sixth, Thrasio, as a gain.
  • Non-accruals fell by 41.5% at cost to $106.1 million, but the list was replaced, not cleared. Six names are on it. Pluralsight ($28.3 million at cost, $9.8 million at fair value) and BioXcel Therapeutics ($7.4 million and $6.4 million) were not flagged at September 30, 2025. Four of the six (Dialyze, SIO2, Pluralsight and BioXcel) are $94.7 million of cost carried at $27.1 million (our arithmetic); the other two, Avery and A.T. Holdings, are carried above their cost.
  • Oaktree's waiver is over and its fees rose while the company's income fell. Base plus Part I incentive fee was $37.0 million in fiscal 2026 against $36.4 million after waivers in fiscal 2025 (+1.7%, our arithmetic), while total investment income fell 10.6% to $283.1 million. Fees were 13.1% of investment income against 11.5% (our arithmetic). In fiscal 2025 Oaktree had waived $20.4 million of the incentive fee.
  • The stock still trades well under book. The 10-K states a last reported price of $12.16 on November 13, 2026, a 22.2% discount to the September 30 NAV of $15.63. The quarterly low prices in fiscal 2026 were 23.7% to 32.2% below that quarter's NAV. The company did not repurchase shares in fiscal 2026 or 2025.
  • The balance sheet was refinanced in September 2026 and one maturity is close. Debt was $1,416.0 million at 1.03x debt to equity (1.00x net), of which 88% is unsecured, after $300 million of 7.000% notes due 2031 repaid revolver borrowings (down from $545.0 million to $166.0 million). The $350.0 million of 2.700% notes falls due on January 15, 2027, 59 days after this filing.

CSV · 282 rows

Oaktree Specialty Lending (OCSL) 10-K for fiscal 2026: NAV, earnings, dividend, non-accruals by company, realized losses, fees, debt and price

282 rows from the Form 10-K for the year ended September 30, 2026 and the November 17, 2026 earnings release: NAV at three dates, earnings, distributions declared, the NAV bridge, non-accruals by company at two year-ends, realized losses, fees, debt and price against NAV. Form and accession number on every row.

What changed between September 30, 2025 and September 30, 2026

The 10-K and the earnings release filed with it give three balance-sheet dates: the year-end before, the June quarter that our earlier page on OCSL's dividend, fee waivers and non-accruals was written from, and this year-end.

MeasureSeptember 30, 2025June 30, 2026September 30, 2026
NAV per share$16.64$15.70$15.63
Net assets$1,465,813 thousand$1,383,055 thousand$1,376,613 thousand
Investments at fair value$2,847,782 thousand$2,741,814 thousand$2,706,366 thousand
Portfolio companies143163170
First lien share of portfolio83.5%81.5%79.1%
Weighted average yield on debt investments9.8%9.3%9.4%
Investments on non-accrual1066
Non-accrual at cost$181,361 thousand$113,573 thousand$106,137 thousand
Non-accrual at fair value$80,689 thousand$47,035 thousand$45,034 thousand
Non-accrual, share of debt at cost6.5%4.2%4.0%
Non-accrual, share of debt at fair value3.0%1.8%1.8%
Total debt, net of financing costs$1,486,880 thousand$1,438,842 thousand$1,384,588 thousand
Debt to equity (net of cash)1.02x (0.97x)1.05x (1.02x)1.03x (1.00x)
Cash$79,630 thousand$39,921 thousand$45,137 thousand

Net assets fell $89.2 million in the year and the portfolio $141.4 million (our arithmetic), while the number of companies rose by 27: the average debt position fell from $20.5 million to $16.8 million, the release says. Unsecured debt rose from 3.2% to 6.1% of the portfolio and equity from 5.0% to 5.5%. The share count did not move: 88,086 thousand shares at both year-ends, and no repurchases in either year (10-K, Item 5).

Earnings against the dividend: the year and the quarter

MeasureQuarter to September 30, 2026Quarter to June 30, 2026Fiscal 2026Fiscal 2025
Total investment income$68,211 thousand$69,433 thousand$283,125 thousand$316,801 thousand
Net expenses$38,163 thousand$36,609 thousand$149,167 thousand$163,300 thousand
Net investment income (GAAP)$29,819 thousand$32,521 thousand$133,405 thousand$152,640 thousand
GAAP NII per share$0.34$0.37$1.51$1.77
Adjusted NII per share$0.34$0.37$1.49$1.76
Net realized and unrealized loss, net of taxes$7,193 thousand$1,581 thousand$93,120 thousand$118,720 thousand
Net increase in net assets from operations$22,626 thousand$30,940 thousand$40,285 thousand$33,920 thousand
Distributions declared per share$0.33$0.34$1.47$1.84

“Adjusted” NII is the company's non-GAAP measure, which leaves out accretion from the accounting of its 2021 and 2023 mergers and capital gains incentive fees; the merger accretion is the reason GAAP NII ($1.51) is $0.02 above adjusted ($1.49). The company attributes the quarter's fall in NII from $0.37 to $0.34 to “lower total investment income and higher income-based (“Part I”) incentive fees (net of fees waived), partially offset by lower interest expense”. Distributions declared in the fiscal year add up to $1.47 ($0.40, $0.40, $0.34 and $0.33), and the 10-K's financial highlights confirm $1.47 of distributions of net investment income with no return of capital, against $1.64 plus $0.20 of return of capital in fiscal 2025.

How the dividend compares with earnings, with our arithmetic on the company's figures:

ComparisonResult (our arithmetic)
Fiscal 2026 adjusted NII ($1.49) over distributions declared ($1.47)101%
Fiscal 2026 GAAP NII ($1.51) over distributions declared ($1.47)103%
Fiscal 2025 adjusted NII ($1.76) over distributions declared ($1.84)96%
Quarter to September 30, 2026: adjusted NII $0.34 over $0.33 declared with the July results103%
Same quarter's adjusted NII over $0.32 payable December 31, 2026106%
$0.32 a quarter against the $0.55 paid each quarter until December 2024-41.8%
$0.32 times four ($1.28) over the $12.16 price of November 13, 202610.5%
$1.28 over NAV of $15.638.2%

The $0.55 comparison uses the first quarter of fiscal 2025, the one declared at $0.55 in the 10-K's Item 5 table. The supplemental is the part to watch: the latest declaration is $0.30 plus $0.02, and our earlier page tracks the base and supplemental history through the July 2026 declaration, when the total was $0.33. At 88,086 thousand shares a $0.32 distribution is $28.2 million (our arithmetic) against $29.6 million of adjusted NII in the quarter. The company's own wording on the source of payments is that “Distributions are paid primarily from distributable (taxable) income” and that “To the extent taxable earnings for a fiscal taxable year fall below the total amount of distributions for that fiscal year, a portion of those distributions may be deemed a return of capital to the Company’s stockholders.”

Per shareFiscal 2026Fiscal 2025
NAV at beginning of year$16.64$18.09
Net investment income$1.51$1.77
Net unrealized appreciation (depreciation)($0.21)($1.18)
Net realized gains (losses)($0.84)($0.20)
Distributions of net investment income($1.47)($1.64)
Tax return of capitalnone($0.20)
NAV at end of year$15.63$16.64

Fiscal 2025 lost its NAV to valuation marks ($1.18 unrealized); fiscal 2026 lost it to realizations ($0.84). The 10-K reconciles the unrealized figure: $66.0 million of unrealized depreciation on debt investments and $37.7 million on equity investments, offset by $80.0 million of unrealized appreciation “related to exited investments (a portion of which resulted in a reclassification to realized losses)”, which is the reversal of marks taken earlier when those loans were sold or written off. The last quarter was quiet: NAV fell $0.07, from $15.70 to $15.63, with NII of $0.34, a $0.08 loss on net realized and unrealized items and $0.33 of distributions (our arithmetic).

The six non-accruals now, and what became of the ten

A loan goes on non-accrual when the company stops recognizing its interest because payment is in doubt. The 10-K's schedule of investments flags each such line with a footnote; adding the flagged lines by company gives these totals, which equal the $181,361 thousand and $80,689 thousand (September 30, 2025) and $106,137 thousand and $45,034 thousand (September 30, 2026) the filing and the release report (our sums of the schedule rows).

CompanyCost, September 30, 2025 ($ million)Fair value, September 30, 2025 ($ million)Cost, September 30, 2026 ($ million)Fair value, September 30, 2026 ($ million)
Dialyze Holdings, LLC30.25.930.25.9
SIO2 Medical Products, Inc.29.411.728.85.0
Pluralsight, LLCnot flaggednot flagged28.39.8
BioXcel Therapeutics, Inc.not flaggednot flagged7.46.4
The Avery Real Estate Operating Companies20.717.67.910.9
A.T. Holdings II SARL4.46.53.57.0
BAART Programs, Inc.19.69.4not flaggednot flagged
Dominion Diagnostics, LLC18.15.4not flaggednot flagged
Astra Acquisition Corp.18.33.5not flaggednot flagged
Mosaic Companies, LLC21.42.5not flaggednot flagged
Thrasio, LLC16.314.7not flaggednot flagged
All Web Leads, Inc.3.03.3not flaggednot flagged
Total181.480.7106.145.0

Three readings that the quarterly filings did not allow. Who left, and at what price. Note 8 of the 10-K lists the realized result for fiscal 2026 by company: Dominion Diagnostics a loss of $24.5 million, Mosaic Companies $18.0 million, Astra Acquisition $16.8 million, BAART Programs $11.3 million and All Web Leads $3.2 million, and Thrasio a gain of $8.8 million. Together that is a net realized loss of $64.9 million on the six names (our arithmetic), against $96.7 million of cost and $38.9 million of fair value carried on non-accrual for those same six names a year earlier (our sums); the realized figures also include equity and other positions in the same companies, so they are not a loss rate on the flagged loans alone. BAART is not a clean exit: the September 30, 2026 schedule shows new first lien term loans to BAART of $0.7 million and $14.4 million of principal at cash rates of 8.90% and 10.07%, plus 7,941,458 shares of preferred equity, none of them flagged.

Who stayed. Dialyze's $30.2 million has not moved in cost or value in twelve months. SIO2 is carried at 17.3% of cost, from 39.8% (our arithmetic). Dialyze, SIO2 and Pluralsight are 82.2% of the cost that remains (our arithmetic). Who came in. Pluralsight had already produced a $35.3 million realized loss in fiscal 2024 (Note 8). At September 30, 2025 its three term loans were carried at their $28.3 million cost, with equity at $8.0 million; at September 30, 2026 the loans are flagged and carried at $9.8 million, and the equity at nil (our arithmetic: $36.3 million to $9.8 million). BioXcel Therapeutics, a pharmaceutical company, is flagged on two 13.00% term loans of $2.1 million and $5.3 million of cost; a third BioXcel loan of $3.6 million of cost is not.

Avery and A.T. Holdings are carried above cost, $18.0 million against $11.5 million (our arithmetic). Take them out and the remaining four names are $94.7 million of cost at $27.1 million of fair value, 28.6% (our arithmetic).

Fees: the waiver ended and the bill went up

Year ended September 30 (USD thousand)202620252024
Base management fee before waiver28,64230,16343,412
Management fees waived09335,250
Part I incentive fee before waiver8,36827,51634,764
Part I incentive fees waived020,3664,438
Base plus Part I fee after waivers (our arithmetic)37,01036,38068,488
Interest expense100,178115,845128,622
Total investment income283,125316,801381,665
Base plus Part I fee as % of investment income (our arithmetic)13.1%11.5%17.9%

The fee schedule changed in two steps: the base fee fell to 1.00% of gross assets on July 1, 2024, and from October 1, 2025 the Part I fee is calculated on income above a preferred return of 1.50% a quarter (6.00% annualized) over the trailing twelve quarters. In fiscal 2025 Oaktree waived $20.4 million of Part I fees under a waiver agreement that ran from October 1, 2024 to September 30, 2025, and the 10-K states that no capital gains incentive fee was incurred in fiscal 2026, while its statement of operations shows no fees waived that year. So the fee Oaktree charged rose by 1.7% (our arithmetic) while total investment income fell 10.6% and NII per share fell 14.7%. The company pays less interest (interest expense fell 13.5%, our arithmetic), which is what kept net expenses down $14.1 million. The same release attributes part of the quarter's $1.6 million rise in net expenses to “higher Part I incentive fees (net of fees waived)”.

The price against NAV

Fiscal quarter (NAV at quarter-end)NAV per shareHigh priceLow priceLow price vs NAV, per the 10-K
Quarter to September 30, 2025$16.64$14.77$12.66(23.9)%
Quarter to December 31, 2025$16.30$14.31$12.44(23.7)%
Quarter to March 31, 2026$15.69$13.06$10.63(32.2)%
Quarter to June 30, 2026$15.70$13.39$10.98(30.1)%
Quarter to September 30, 2026$15.63$13.33$11.56(26.0)%
October 1 to November 13, 2026not determinable$12.79$11.19not determinable

On November 13, 2026 the last price was $12.16, a 22.2% discount to NAV at September 30, 2026 in the company's words. The market value per share at the end of fiscal 2026 was $11.90 against $13.05 a year earlier (-8.8%, our arithmetic), and the 10-K's total return on market value for the year was 2.76%, which includes distributions. Prices since October 1, 2026 are above the $10.63 low of the quarter to March 31, 2026, but the stock did not trade at or above NAV in any quarter in the table. The 10-K counts 46 stockholders of record, which excludes people whose shares are held through a broker.

Debt, and the January 2027 maturity

Debt (principal)September 30, 2025September 30, 2026Maturity
Syndicated revolving facility$545.0 million$166.0 millionper the credit agreement
2.700% Notes$350.0 million$350.0 millionJanuary 15, 2027
7.100% Notes$300.0 million$300.0 millionFebruary 15, 2029
6.340% Notes$300.0 million$300.0 millionFebruary 27, 2030
7.000% Notes (issued September 16, 2026)none$300.0 millionSeptember 16, 2031
Total$1,495.0 million$1,416.0 million

For the year the company made $379.0 million of net repayments under its credit facilities and received $299.9 million from issuing unsecured notes. Asset coverage was 195.00% at September 30, 2026 (197.50% a year earlier). Under the reduced asset coverage requirement its stockholders approved in 2019, the 10-K says the company “can incur $2 of debt for each $1 of equity”, and its target debt to equity range is 0.90x to 1.25x. The weighted average interest rate on debt, including swaps, rose from 5.9% to 6.2% because of the 7.000% coupon. Liquidity was $45.1 million of cash and $994.0 million of undrawn capacity on the credit facility, subject to the borrowing base. Unfunded investment commitments were $252.6 million. The contractual-obligations table in the 10-K shows $350.0 million of 2027 Notes plus $5.8 million of interest due within one year, and the earnings presentation says liquidity was “relatively unchanged” on the assumption that the 2027 Notes are repaid at maturity with borrowings under the credit facility, which is the company's stated plan, not a certainty.

If your shares came from Oaktree Strategic Income II

OCSL acquired Oaktree Strategic Income II, Inc. (OSI2) on January 23, 2023, when, as the 10-K says, OSI2 was merged into it. Someone who held OSI2 shares before that and still holds what the merger gave them is exposed to OCSL's NAV and to a listed price, not to a fund's repurchase limits. The two numbers in this filing are NAV of $15.63 and the price of $12.16 on November 13, 2026; both come with the note that OCSL's NAV is set from the portfolio's valuations at each quarter-end, and prices move daily. Oaktree's non-traded vehicles that still have repurchase limits are covered on our pages on Oaktree Strategic Credit Fund and Oaktree Asset-Backed Income Fund.

What a holder can do with this

This is a checklist built from the documents, not a recommendation.

  • Plan on $0.30 and treat the rest as variable. The total declared fell from $0.34 to $0.33 to $0.32 across the last three declarations (10-K, Item 5), with $0.02 of the latest one a supplemental, and the 8-K gives no commitment for the next one.
  • Compare earnings with the whole payout, not the base. Fiscal 2026 adjusted NII was $1.49 against $1.47 declared; the cushion in the quarter was $0.02 a share on the new $0.32.
  • Read the non-accrual list by name. Six names, four of them carried at 28.6% of cost; the two carried above cost are Avery and A.T. Holdings.
  • Ask what Oaktree is paid now. The waiver is over: $37.0 million of base and incentive fees on $283.1 million of income.
  • Check the date. The record date is December 15, 2026 and the payment December 31, 2026; the 2027 Notes mature January 15, 2027.
  • Look at your 1099-DIV, not the release, for tax. The 10-K shows no return of capital for fiscal 2026 on a per-share basis; the character of your own distributions is on your form. We do not give tax advice.

This is analysis of public documents, not investment, legal or tax advice. We do not give price targets or say whether to buy, sell or hold.

FAQ

All figures are from Oaktree Specialty Lending Corporation's filings on SEC EDGAR (CIK 1414932), read on November 17, 2026: the Form 10-K for the year ended September 30, 2026 (accession 0001414932-26-000023, document ocsl-20260930.htm, filed November 17, 2026) including Item 5, the financial highlights, the statements of operations and of changes in net assets, the schedules of investments at September 30, 2026 and 2025, Notes 8 and 10 and the subsequent events note; and the Form 8-K of November 17, 2026 (accession 0001193125-26-464682) with its Exhibit 99.1 earnings release and Exhibit 99.2 earnings presentation. Dollar amounts are as the filings state them; per-share and percentage changes marked “our arithmetic” are ours. This is analysis of public documents, not investment, legal or tax advice.

Affiliate Disclosure: Some links are affiliate links. We may earn a commission at no extra cost to you. This does not affect our ratings. Learn more.